Replies to post #2822 on Ariad Pharmaceuticals Inc fka ARIA

[biotech_researcher]

Harvey might be a mad man based on this statement today:

"Importantly, the Company anticipates that this funding will allow ARIAD to retain the substantial potential commercial value of ponatinib in multiple lines of treatment for chronic myeloid leukemia (CML) and other cancers by focusing its partnering strategy on a regional collaboration in select markets outside of the U.S. The Company does not intend to pursue a global partnership for ponatinib."

He hasn't learned his lesson. This is the stratagy he followed with Ridaforolimus. He will HAVE to do ANOTHER secondary in early 2012 to survive..